Home » Industry News »
Axi-cel CAR-T therapy extends EFS in patients with R/R large B-cell lymphoma
The randomised phase 3 trial included 359 patients that were randomly assigned a single fusion of axi-cel or standard-of-care therapies for R/R large B-cell lymphoma…
Real-world data (RWD) to identify target population for new CAR-T therapies
Data was obtained through the linking of EHD The annual incident number of DLBCL was estimated to be 329 which multiplied by R2-rate (13.7%) gives…